IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 174 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.11 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,024,750 | +343.1% | 445,000 | +584.6% | 0.68% | +390.6% |
| Q2 2023 | $456,950 | +33.8% | 65,000 | +16.1% | 0.14% | +46.3% |
| Q1 2023 | $341,600 | -4.4% | 56,000 | 0.0% | 0.10% | -13.6% |
| Q4 2022 | $357,280 | -33.3% | 56,000 | 0.0% | 0.11% | -36.0% |
| Q3 2022 | $536,000 | -99.8% | 56,000 | +1759.8% | 0.17% | -94.0% |
| Q2 2022 | $273,000,000 | +9526.2% | 3,011 | -94.8% | 2.85% | +345.0% |
| Q1 2022 | $2,836,000 | +156.4% | 58,000 | 0.0% | 0.64% | +160.2% |
| Q4 2021 | $1,106,000 | -22.7% | 58,000 | 0.0% | 0.25% | -28.7% |
| Q3 2021 | $1,430,000 | -5.2% | 58,000 | 0.0% | 0.34% | -13.3% |
| Q2 2021 | $1,509,000 | -17.8% | 58,000 | 0.0% | 0.40% | -18.1% |
| Q1 2021 | $1,836,000 | -31.8% | 58,000 | 0.0% | 0.49% | -33.9% |
| Q4 2020 | $2,693,000 | -43.6% | 58,000 | -60.0% | 0.74% | -52.3% |
| Q3 2020 | $4,773,000 | +87.7% | 145,000 | +39.4% | 1.54% | +63.4% |
| Q2 2019 | $2,543,000 | – | 104,000 | – | 0.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |